Avantor Results Presentation Deck

Q3 performance Organic revenue Adjusted EBITDA growth Fully diluted adjusted EPS growth Free cash flow Adjusted net leverage avantor™ 10.2% 25.8% 47.6% $229.3M 3.5X 1: Excludes equity issuance proceeds of ~$970M - Volume, inflation management & proprietary growth - ~180bps margin expansion - - Strong growth in all regions led by Biopharma -8.5% Core / -1.7% COVID-19 tailwinds - Continued track record of execution Lower interest and tax expense Strong EBITDA performance partially offset by growth investments Higher cash tax timing and CARES ACT expiry Down 0.3X from Q2¹ Committed to 2-4X target leverage LO 5

View entire presentation